Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Companies

GSK, INNOVAX and Xiamen University to jointly develop cervical cancer vaccine

Xinhua | Updated: 2019-09-07 14:26
Share
Share - WeChat
The logo of GlaxoSmithKline (GSK) is seen on its office building in Shanghai. [Photo/Agencies]

BRUSSELS - INNOVAX, a subsidiary of China's YangShengTang Group, and Xiamen University signed a global alliance partnership agreement on Friday with British pharmaceutical giant GlaxoSmithKline (GSK) in Wavre, Belgium, to develop a next-generation vaccine against human papillomavirus (HPV).

Zhong Shanshan, chairman of YangShengTang Group, announced this in an interview with Xinhua.

This vaccine will combine the innovative antigen detection method developed by Prof Xia Ningshao's team at Xiamen University, with GSK's proprietary adjuvant AS04, which leverages this antigen technology.

Shazia Sheikh, director of public affairs for global and emerging markets at GSK Vaccine, confirmed the news via email on Friday.

Zhong stressed that this is the first time a Chinese vaccine company, by leveraging its original technology, has entered into a partnership with a world leading vaccine company to co-develop and ultimately commercialize an important vaccine globally. This alliance shows that China's vaccine technology has been highly regarded by its international counterparts. And the partnership is an exemplary collaboration between the pharmaceutical industries of China and Europe.

Zhang Rong, president of Xiamen University, told Xinhua that biological research at Xiamen University has a history of nearly one hundred years. Making scientific and technological achievements that are beneficial to human health and wellbeing and promoting their commercialization is consistent with the University's mission.

"This partnership is a milestone in the past 20 years of industry-research collaboration between INNOVAX and Xiamen University. It is also a commercial cooperation between a Chinese vaccine company and a global vaccine company from Europe. But, above all, it is a model of how the international academic and industrial community can join hands to fight human diseases," he added.

Under the agreement, INNOVAX will build a vaccine production line in Xiamen, Southeast China, that will comply with the standards set by China, the United States, the European Union and the World Health Organization. It will produce and provide to GSK various types of HPV vaccine antigens, which will then be combined with GSK's patented AS04 adjuvant to develop new HPV vaccines for worldwide commercialization, including in Europe and the United States.

GSK said the partnership with INNOVAX will accelerate the development of the next generation of its cervical cancer vaccine.

According to Zhong, the antigen technology was born in the joint biopharmaceuticals laboratory of Xiamen University and YangShengTang led by Professor Xia. It successfully used DNA recombination technology to express proteins in E coli and used it for vaccine production. INNOVAX's cervical cancer vaccine is highly effective in that it protects more HPV types with fewer virus-like particles (VLPs).

The bivalent cervical cancer vaccine co-developed by INNOVAX and Prof. Xia's team is the first Chinese cervical cancer vaccine that has completed the Phase III clinical trial. Commercialization of this vaccine will make China the world's third country with the ability to independently manufacture cervical cancer vaccines after the US and the UK. GSK accelerated partnership talks between the two parties in November, 2018, when INNOVAX's Phase III clinical trial data on cervical cancer vaccine were released.

The cervical cancer vaccine has broad market prospects globally. Cervical cancer is the third most common cancer in women. It is estimated that every year 311,365 women are killed and in every two minutes, a woman will die of cervical cancer. Almost all cases of cervical cancer are caused by the human papillomavirus (HPV). Over 100 types of HPV virus are known, and over 15 of them can cause cervical cancer.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 亚洲天堂五月天| 国产一区二区三区精品视频 | 久久精品国产亚洲AV蜜臀色欲 | 91精品国产高清久久久久| 攵女yin乱合集小丹| 亚洲人成在线播放网站| 狼人久久尹人香蕉尹人| 国产va在线视频观看| 免费h片在线观看网址最新| 图片区偷拍区小说区| 东京一本一道一二三区| 日韩三级电影院| 亚洲国产欧美一区二区欧美| 男女性杂交内射女BBWXZ| 国产aaa女人十八毛片| 99自拍视频在线观看| 国产精品自在线天天看片| japanese日本护士xxxx18一19 | 免费观看我爱你电影| 被两个体育生双龙9| 国产欧美日韩va| 91久久国产精品| 奇米第四色首页| 中文字幕av一区乱码| 日韩中文字幕免费| 亚洲人成亚洲人成在线观看| 涂了媚药的玉势| 免费看一级做a爰片久久| 老司机在线精品| 国产做受视频激情播放| 欧美jlzz18性欧美| 国产精品无码久久久久| 99在线精品视频在线观看| 小信的干洗店1~4| 中文字幕乱码系列免费| 日本动态图免费观看| 久久精品视频免费看| 欧美乱强伦xxxxx高潮| 亚洲欧美校园春色| 狠狠躁天天躁中文字幕无码| 凹凸在线无码免费视频|